FDA Approves Pasatru for Fibrodysplasia Ossificans Progressiva
Food and Drug Administration (FDA) has approved Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP) to reduce new heterotopic ossification and decrease clinician-assessed disease flare-ups.